Dr. Bouzyk is Co-Founder and Chief Scientific Officer of AKESOgen, Inc., a genomics, pharmacogenomics and biobanking company based in the greater Atlanta region, Georgia, USA. Prior to AKESOgen, Dr. Bouzyk spent 5 years as a faculty member in the Department of Human Genetics at Emory University, Atlanta, Georgia. During his tenure at Emory he served as a Director of the Emory Biomarker Service Center (EBSC), Director, Basic Research Shared Core Resources, Emory Winship Cancer Institute, Emory University as well as Director of the Center for Medical Genomics -which he established.
Prior to joining Emory Dr. Bouzyk spent approximately 9 years at GlaxoSmithKline (GSK), where he served as Director of Genetic Laboratory Sciences leading the company's high throughput genomics efforts in Europe. Dr. Bouzyk has also held scientific positions at Cancer Research UK and the Medical Research Council in the UK. Dr. Bouzyk's interests lie in Pharmacogenetics as well as candidate gene and genomic association studies to identify genes for both common and rare diseases.

Abstract:

DATE: October 25, 2017
TIME: 08:00am PDT, 11:00am EDT

As we learn more about the implications of genetic variation in 21st century medicine, the utilization of genotyping as a molecular tool both in the research and clinical setting is as important and popular as ever. This presentation will exemplify the power and precision of the Applied Biosystems™ Axiom™ genotyping platform in several settings. Examples will include the use of Applied Biosystems™ Axiom™ Genotyping Arrays in the Department of Veterans Affairs’ Million Veteran Program (MVP), the use of the Applied Biosystems™ Axiom™ Precision Medicine Research Array, the use of the Applied Biosystems™ PharmacoScan Solution for pharmacogenetics, as well as using a unique custom array for potential dementia risk assessment. The talk will be presented from the perspective of a global service provider.

In this webinar, Dr. Mark Bouzyk will:

Demonstrate the flexibility and accuracy of the Axiom Genotyping platform and how it is particularly suitable for large-scale genomic studies

Explain how the recently developed Axiom Precision Medicine Research Array can be used in a wide variety of disease and therapeutic research areas

Discuss new arrays including the PharmacoScan Solution for pharmacogenomics research and a custom Axiom array for dementia, particularly Alzheimer’s disease, and the usefulness of these arrays in clinical research trials for stratifying populations

For Research Use Only. Not for use in diagnostic procedures.

Show Resources

Please update your information

Certificate of Attendance

Thank you for choosing LabRoots. Please note that a Certificate of Attendance does NOT count towards Continuing Education Credits.